Homepage
Author:
Propanc Biopharma, Inc.
Posted Date:
March 24, 2026
Propanc Biopharma Executes Multi-Yr, Anti-Aging & Cancer Research Collaboration with the Universities of Jaén and Granada, Spain
Propanc Biopharma, Inc.
March 24, 2026
Propanc Biopharma Targets $3B+ Pancreatic Cancer Market with PRP: 85%+ Tumor Inhibition in Breakthrough Proenzyme Therapy
Propanc Biopharma, Inc.
March 12, 2026
Propanc Biopharma Executes Service Agreement with FyoniBio to Establish & Validate Pharmacokinetics Assay for Phase 1b First-In-Human Study
Propanc Biopharma, Inc.
March 10, 2026
Propanc Biopharma’s Lead Asset PRP Shows >85% Tumor Growth Inhibition in Preclinical Pancreatic Models
Propanc Biopharma, Inc.
March 3, 2026
Propanc Biopharma Provides Corporate Update and Reports Half Yearly 2025/26 Results
Propanc Biopharma, Inc.
February 18, 2026
Propanc Biopharma Unveils PRP: A Game-Changing Proenzyme Therapy Poised to Challenge Standard Cancer Treatments in the $3+ Billion Pancreatic Cancer Market
Propanc Biopharma, Inc.
February 8, 2026
Propanc Biopharma Accelerates IP Momentum: Files Fourth Provisional Patent Application in Just Two Months – Strengthening Global Protection for Breakthrough Proenzyme Formulations
Propanc Biopharma, Inc.
January 28, 2026
